22:33 , Oct 4, 2018 |  BC Innovations  |  Tools & Techniques

No crisp upper hand in CRISPR

While the most recent ruling in the ongoing CRISPR IP battle maintained the Broad Institute’s dominant patent position in the U.S., University of California Berkeley’s dominant position in Europe, coupled with the looming possibility of...
17:16 , Jul 20, 2018 |  BC Week In Review  |  Company News

Cas3 antimicrobial company acquires Epibiome tech

Locus Biosciences Inc. (Research Triangle Park, N.C.) acquired a phage discovery platform from fellow antibacterial company EpiBiome Inc. (South San Francisco, Calif.) in an all-stock deal. Locus declined to disclose financial terms. Locus launched in...
13:00 , Jul 17, 2018 |  BC Extra  |  Company News

Cas3 antimicrobial company acquires EpiBiome tech

Locus Biosciences Inc. (Research Triangle Park, N.C.) acquired a phage discovery platform from fellow antibacterial company EpiBiome Inc. (South San Francisco, Calif.) in an all-stock deal. Locus declined to disclose financial terms. Locus launched in...
05:08 , Nov 17, 2017 |  BC Week In Review  |  Financial News

Venture roundup: ImmusanT, Locus

On Nov. 14, autoimmune company ImmusanT Inc. (Cambridge, Mass.) and antimicrobial play Locus Biosciences Inc. (Research Triangle Park, N.C.) announced venture financings totaling nearly $60 million. ImmusanT raised $40 million in a series C round...
00:11 , Nov 15, 2017 |  BC Extra  |  Financial News

Venture Roundup: ImmusanT, Locus

On Tuesday, autoimmune company ImmusanT Inc. (Cambridge, Mass.) and antimicrobial play Locus Biosciences Inc. (Research Triangle Park, N.C.) announced venture financings totaling nearly $60 million. ImmusanT raised $40 million in a series C round led...
21:12 , Sep 27, 2017 |  BC Innovations  |  Emerging Company Profile

Sparing the microbiome

Eliminating disease-causing bacteria from the gut while sparing healthy commensal bacteria is one of the key challenges of creating microbiome-based therapies. Eligo Bioscience S.A.S. has a platform that couples the editing power of CRISPR with...
17:34 , Aug 31, 2017 |  BC Innovations  |  Product R&D

Cutting through resistance

Most companies employing CRISPR- Cas9 for therapeutics are using it to edit human cells, but Locus Biosciences Inc. is betting the lesser-known CRISPR- Cas3 system will do a better job of treating bacterial infections and...